Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (DE:RHO5)
FRANKFURT:RHO5
RHO5 Stock Chart & Stats
€377.50
€0.00(0.00%)
At close: 4:00 PM EST
€377.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€244.35 - €411.60
Previous CloseN/A
Volume2.84K
Average Volume (3M)397.00
Market Cap
$294.47B
Enterprise Value€290.64B
Total Cash (Recent Filing)$15.48B
Total Debt (Recent Filing)$31.64B
Price to Earnings (P/E)20.3
Beta0.23
Next Earnings
Jul 23, 2026EPS Estimate
11.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.30
Shares Outstanding702,562,700
10 Day Avg. Volume250
30 Day Avg. Volume397
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue4.72
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda12.83
Forecast
1Y Price Target
$388.16Price Target Upside2.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)22.37
Revenue Forecast (FY)$69.58B
Bulls Say, Bears Say
Bulls Say
Adjuvant Market OpportunityGiredestrant targets most hormone receptor–positive, HER2‑negative breast cancer patients and appears better tolerated than standard therapy, supporting a large adjuvant market opportunity if regulators allow label flexibility for switching from aromatase inhibitor monotherapy.
Clinical Trial EfficacyFENhance trials showed fenebrutinib substantially reduced relapse rates and brain lesion activity versus the comparator, supporting a stronger efficacy profile in relapsing multiple sclerosis.
Diagnostics Innovation And GrowthRoche's new sequencing platform, proprietary sensor chip and automated mass spectrometry could create scalable advantages that challenge incumbents, expand testing capabilities and help offset pharmaceutical revenue pressure.
Bears Say
Analyst Sentiment And Trial RiskPrior negative outcomes in high‑risk trials and remaining questions on statistical significance and toxicity keep analyst sentiment cautious and may weigh on valuation until clearer data are available.
Evidence And Adoption RiskBroader use of giredestrant, particularly in combination with CDK4/6 inhibitors, may require definitive randomized data to convince clinicians and payers, creating uncertainty around uptake.
Safety And Regulatory RiskAn imbalance in fatal outcomes and reports of liver injury associated with fenebrutinib raises material safety concerns that could constrain regulatory approval and limit commercial potential.
Roche Holding AG News
RHO5 FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was €244.35 and its highest was €411.60 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $294.47B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 134 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported €9.299 earnings per share for the quarter, missing the consensus estimate of €9.454 by -€0.155.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 11.94.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of €9.299 in its last earnings report, missing expectations of €9.454. Following the earnings report the stock price went up 3.63%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in DE:RHO5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHO5 Company Deck
RHO5 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all DE:RHO5 earnings summariesRHO5 Stock 12 Month Forecast
Average Price Target
€388.16
▲(2.82% Upside)
Technical Analysis
Options Prices
Currently, No data available
---